tive behaviour. The company is offering the drug Clomicalm along with guidelines for owners on how to improve their dogs` behaviour. The drug will be marketed in Europe first after being approved by European Union regulators. Permission is being sought in other world markets including the United States, Novartis said. Novartis`s animal health division makes a variety of drugs for veterinary problems ranging from fleas to heart conditions. Studies indicate that 15 percent of dogs suffered from separation anxiety, the company said, adding: "It has long been recognised that behavioural disorders can seriously affect a pet`s overall health."